Related Experiment Videos
CPH 82 (Reumacon) in refractory inflammatory arthritis
E S Gudmundsdóttir1, H Jónsson
1Landspitalinn University Hospital, Reykjavik, Iceland.
Scandinavian Journal of Rheumatology
|November 28, 2000
Summary
CPH 82 demonstrated good clinical tolerance and no serious side effects in Icelandic patients with severe refractory arthritis. Drug survival rates were moderate, with 16% discontinuing due to side effects.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Severe refractory arthritis poses significant treatment challenges.
- Disease-modifying antirheumatic drugs (DMARDs) are crucial for managing inflammatory arthritis.
- Limited treatment options exist for patients with refractory disease.
Purpose of the Study:
- To evaluate the clinical tolerance and drug survival of CPH 82.
- To assess the safety profile of CPH 82 in patients with severe refractory arthritis.
- To analyze the efficacy of CPH 82 as a monotherapy or in combination with other DMARDs.
Main Methods:
- Retrospective analysis of 44 Icelandic patients with severe refractory arthritis.
- Data collection on drug tolerance, side effects, and discontinuation rates.
- Assessment of drug survival over a three-year period.
Main Results:
- CPH 82 exhibited good clinical tolerance.
- No serious adverse events were reported.
- 16% of patients discontinued CPH 82 due to side effects.
- The three-year drug survival rate was 51%.
Conclusions:
- CPH 82 appears to be a well-tolerated treatment option for severe refractory arthritis.
- Further research is warranted to optimize CPH 82 treatment strategies.
- CPH 82 may offer a viable therapeutic alternative for refractory arthritis patients.